Vietnam is rapidly embracing point-of-care (POC) diagnostics as healthcare providers seek faster, more accessible and more efficient ways to diagnose disease. From emergency departments and community clinics to pharmacies and patients' homes, portable diagnostic technologies are transforming how healthcare is delivered across the country.
According to IMARC Group, Vietnam's Point-of-Care Diagnostics Market reached US$230.5 million in 2025 and is projected to grow to US$465.4 million by 2034. The market is benefiting from increasing demand for rapid testing, advances in diagnostic technology and continued investment in healthcare infrastructure.
Point-of-care diagnostics enable healthcare professionals to perform laboratory-quality tests close to the patient, delivering results within minutes rather than hours or days. This reduces diagnostic delays, supports earlier treatment decisions and improves patient outcomes, particularly in emergency medicine, infectious disease management, chronic disease monitoring and primary care.
The market encompasses a broad range of technologies, including:
- Blood glucose monitoring systems
- Rapid infectious disease tests
- Cardiac marker tests
- Pregnancy and fertility testing
- Cholesterol and lipid testing
- Coagulation monitoring
- Molecular point-of-care diagnostics
- Lateral flow immunoassays
- Microfluidic diagnostic platforms
- Portable biosensor technologies
Several structural trends are supporting continued market expansion across Vietnam:
- Increasing prevalence of diabetes and cardiovascular disease.
- Continued demand for rapid infectious disease detection.
- Expansion of decentralised healthcare services.
- Growing investment in primary healthcare and community clinics.
- Rising adoption of home-based diagnostic testing.
- Advances in portable molecular diagnostic technologies.
- Government programmes supporting healthcare modernisation and disease surveillance.
One of the fastest-growing segments is molecular point-of-care testing. IMARC Group estimates Vietnam's Point-of-Care Molecular Diagnostics Market reached US$43.9 million in 2025 and is forecast to reach US$81.0 million by 2034. Portable PCR platforms, isothermal amplification technologies and microfluidic systems are enabling laboratory-grade molecular testing in hospitals, clinics and community healthcare settings, significantly improving diagnosis of infectious diseases such as tuberculosis and respiratory infections.
The wider diagnostics sector continues to provide strong momentum. According to IMARC Group, Vietnam's In Vitro Diagnostics (IVD) Market reached US$349.3 million in 2025 and is expected to grow to US$503.6 million by 2034, driven by rising healthcare awareness, increasing chronic disease prevalence, population ageing and technological innovation. Point-of-care diagnostics are becoming an increasingly important component of this broader diagnostics ecosystem by bringing testing closer to patients and reducing reliance on central laboratories.
Clinical diagnostics is also expanding rapidly. IMARC Group reports Vietnam's Clinical Diagnostics Market reached US$459.8 million in 2025 and is projected to reach US$773.4 million by 2034, supported by government investment in laboratory infrastructure, greater adoption of digital health technologies and growing demand for preventive healthcare. Point-of-care testing complements these investments by enabling earlier diagnosis and reducing pressure on central laboratory services.
Technology continues to reshape the market. Artificial intelligence is being integrated into portable diagnostic platforms to improve interpretation accuracy, while cloud connectivity allows clinicians to monitor results remotely and integrate them directly into electronic health records. Biosensors, lab-on-a-chip technologies and smartphone-connected diagnostic devices are making testing faster, smaller and more accessible, particularly in rural and underserved communities. Advances in optical biosensors and microfluidic systems are expected to further accelerate adoption over the coming decade.
Leading manufacturers including Abbott, Roche Diagnostics, Siemens Healthineers, Danaher (Cepheid), QuidelOrtho, BD (Becton Dickinson), Thermo Fisher Scientific, bioMérieux, Qiagen and Sysmex continue to invest in next-generation point-of-care testing platforms covering infectious diseases, cardiology, diabetes, oncology and molecular diagnostics.
As Vietnam modernises its healthcare system and expands access to diagnostic services, point-of-care diagnostics are expected to play an increasingly central role in improving clinical outcomes, reducing healthcare costs and expanding access to quality care. For manufacturers of rapid diagnostic tests, biosensors, portable molecular diagnostics, digital health platforms and connected medical devices, Vietnam represents one of Southeast Asia's most attractive long-term growth opportunities.